ArabFinance: Kahira Pharmaceuticals and Chemical Industries Company (CPCI) reported a 22.47% year-on-year growth in net profit after tax for the first half (H1) of fiscal year (FY) 2021/2022, according to the company’s unaudited financial indicators filed to the Egyptian Exchange (EGX).
CPCI’s net profit after tax stood at EGP 82.05 million for the six-month period ended December 31st 2021, compared to profits of EGP 67.004 million the year before, as per the statement.
Revenue amounted to EGP 527.10 million in H1 FY 2021/2022, down from EGP 532.23 million in the comparative period a FY earlier.
Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.
Copyright 2022 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).